SIASUN(SZ:300024) Zhong Guo Xin Wen Wang·2025-11-18 10:22Core Viewpoint - The successful implementation of China's first second-generation vascular interventional robot for neurosurgery marks the entry into the "robotic diagnosis and treatment 2.0 era" in China, showcasing a globally leading independent innovation solution through deep integration of medical research and production [1][4]. Group 1: Surgical Innovation - The neurosurgery was performed at Shenzhen Second People's Hospital, where the lead surgeon operated the robot from behind a radiation-free lead glass, eliminating the need for heavy lead aprons [3]. - The patient reported minimal discomfort post-surgery and was able to get out of bed the next day, highlighting the efficiency and stability of the robotic procedure [3]. Group 2: Technological Advancements - The second-generation PANVIS STAR robot features four core advantages: low radiation, precise operation, 5G remote control, and sensitive feedback, which collectively enhance surgical safety and accessibility [4]. - The robot's development was a collaborative effort led by a team from Southern University of Science and Technology and a local enterprise, emphasizing the importance of the "medical-research-production" collaborative innovation model [4]. Group 3: Impact on Healthcare - The introduction of this robotic technology addresses the challenges of traditional neurosurgery, such as prolonged exposure to radiation for surgeons and the uneven distribution of medical resources, thereby improving patient care accessibility [3][4].